Targeting the arginine metabolic brake enhances immunotherapy for leukaemia

Therapeutic approaches which aim to target Acute Myeloid Leukaemia through enhancement of patients’ immune responses have demonstrated limited efficacy to date, despite encouraging preclinical data. Examination of AML patients treated with azacitidine (AZA) and vorinostat (VOR) in a Phase II trial,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mussai, Francis, Wheat, Rachel, Sarrou, Evgenia, Booth, Sarah, Stavrou, Victoria, Fultang, Livingstone, Perry, Tracey, Kearns, Pamela, Cheng, Paul, Keeshan, Karen, Craddock, Charles, De Santo, Carmela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Tumor Immunology and Microenvironment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767531/
https://www.ncbi.nlm.nih.gov/pubmed/30485425
http://dx.doi.org/10.1002/ijc.32028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767531/
https://www.ncbi.nlm.nih.gov/pubmed/30485425
http://dx.doi.org/10.1002/ijc.32028

Ejemplares similares